Design and synthesis of potent, isoxazole-containing renin inhibitors. 2012

Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
Merck Frosst Centre for Therapeutic Research, Kirkland, Québec, Canada. pierre-andre_fournier@merck.com

The design and optimization of a novel isoxazole S(1) linker for renin inhibitor is described herein. This effort culminated in the identification of compound 18, an orally bioavailable, sub-nanomolar renin inhibitor even in the presence of human plasma. When compound 18 was found to inhibit CYP3A4 in a time dependent manner, two strategies were pursued that successfully delivered equipotent compounds with minimal TDI potential.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
January 1992, Journal of medicinal chemistry,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
January 2011, Bioorganic & medicinal chemistry letters,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
October 1986, Journal of medicinal chemistry,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
October 1999, Chemical & pharmaceutical bulletin,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
February 2018, Bioorganic & medicinal chemistry letters,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
September 2010, European journal of medicinal chemistry,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
June 2009, Journal of medicinal chemistry,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
November 2017, Molecules (Basel, Switzerland),
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
April 2023, Natural product research,
Pierre-André Fournier, and Mélissa Arbour, and Elizabeth Cauchon, and Austin Chen, and Amandine Chefson, and Yves Ducharme, and Jean-Pierre Falgueyret, and Sébastien Gagné, and Erich Grimm, and Yongxin Han, and Robert Houle, and Patrick Lacombe, and Jean-François Lévesque, and Dwight MacDonald, and Bruce Mackay, and Dan McKay, and M David Percival, and Yeeman Ramtohul, and René St-Jacques, and Sylvie Toulmond
August 1992, International journal of peptide and protein research,
Copied contents to your clipboard!